These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Hemodynamic effects of single-dose administration of AR-L 115 BS in patients with coronary artery disease.
    Author: Weikl A, Kohlschütter S, Durst OE, Lang E.
    Journal: Arzneimittelforschung; 1981; 31(1a):244-7. PubMed ID: 7195232.
    Abstract:
    2-[(2-Methoxy-4-methylsulfinyl)phenyl]-1H-imidazo[4,5-b]pyridine (AR-L 115 BS) was investigated in 14 patients with coronary artery disease (CAD) and an elevated left ventricular enddiastolic pressure at rest (LVEDP). There was a significant decrease in the systolic (AOPS) and diastolic aortic pressures (AOPD) of 9% and 6%, respectively, (p less than 0.001, p less than 0.01). The LVEDP decreased by 29% (p less than 0.001), and the maximum rate of pressure rise (dp/dt max) increased by 19% (p less 0.001). The systolic (PAPS) and diastolic pulmonary artery pressures (PAPD) fell by 17% and 16%, respectively (p less than 0.05). The cardiac index (CI) increased by 12% (p less than 0.05), and the peripheral resistance (SVR) fell by 17% (p less than 0.001). Heart rate increased slightly by 5% (p less than 0.1) but this was of no clinical relevance. The right atrial pressure (RAP) and the tension time index (TTI) remained unchanged. AR-L 15 BS was observed to have vasodilating and positive inotropic effects without increasing oxygen consumption. It can therefore be recommended for use in patients with CAD and an elevated LVEDP. Side-effects have not been reported.
    [Abstract] [Full Text] [Related] [New Search]